Company news
Hemostemix Inc news in 2026
Hemostemix Inc's news releases, calls and decks from 2026, newest first.
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update
October 7, 2026
Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit
September 28, 2026
Hemostemix Non Brokered Private Placement
September 23, 2026
Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA
August 20, 2026
Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell(TM) Longevity Clinical Trial
August 12, 2026
Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026
July 30, 2026
Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell(TM)'s Excellent Results
July 28, 2026
Hemostemix grants 6,280,000 options
July 22, 2026
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
July 8, 2026
Hemostemix Closes $360,000 First Tranche of Private Placement
June 26, 2026
Hemostemix' $1,000,000 Private Placement and Update
June 17, 2026
Dr. Desiree Cox Appointed to Hemostemix Board of Directors
May 26, 2026
Dr. Desirée Cox Appointed to Hemostemix’ Board of Directors
May 25, 2026
$1,000,000 Private Placement
May 21, 2026
Hemostemix closes $303,967 private placement at $0.12 per share
March 19, 2026
Hemostemix Leadership Attending Abundance360 Summit
March 9, 2026
Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships
February 3, 2026
Hemostemix Receives FDA Support for Its Basket Protocol Approach
January 16, 2026
Decks in 2026
- Investor Presentation (2026)
Investor deck · 23 slides · 2026